FDA Role In Prioritizing Pediatric Oncologic Development On Cmte. Agenda

FDA's Pediatric Oncology Subcommittee should consider whether the agency should contribute to the prioritization of development of pediatric oncologic therapies, participants in FDA's workshop on pediatric oncology drug development agreed